Pioneering skin longevity brand OneSkin landed a $20 million Series A investment, marking a significant milestone in the brand’s growth.WHO: Founded by four Brazilian PhD scientists in 2016, OneSkin is the first brand to focus exclusively on extending skinspan—the period during which skin remains healthy and functional—by using rigorous scientific research to target the underlying mechanisms of aging, not just surface appearance. Their approach centers around longevity science, particularly targeting senescent cells—the aging cells that accumulate in skin over time and contribute to inflammation, collagen breakdown, and visible signs of aging. OneSkin's proprietary peptide, OS-01, is designed to reduce the burden of these senescent cells, aiming to make older skin look and behave like younger skin.Prelude Growth Partners, a New York-based growth equity firm, is known for backing high-growth, founder-led consumer brands. They make investments of $15 million to $75 million. Representative past and current partner investments include: Bachan’s, Banza, Blueland, Fly By Jing, MadeGood, So Good So You, Skin Pharm, Sol de Janeiro, Summer Fridays, The Center Brands (including Naturium and PHLUR), Tower 28, and Westman Atelier.WHY: Unlike traditional funding rounds, OneSkin was not actively seeking new capital. Prelude Growth Partners proactively approached the brand with a desire to invest, and OneSkin leveraged the opportunity to replace an early seed stage investor with a partner who could best support them in this next stage of growth.